



(11) **EP 4 431 154 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
11.12.2024 Bulletin 2024/50

(43) Date of publication A2:
18.09.2024 Bulletin 2024/38

(21) Application number: **24173629.7**

(22) Date of filing: **11.02.2019**

(51) International Patent Classification (IPC):
A61K 31/506 ^(2006.01) **A61K 31/337** ^(2006.01)
A61K 31/475 ^(2006.01) **A61K 31/519** ^(2006.01)
A61K 31/555 ^(2006.01) **A61K 31/7048** ^(2006.01)
A61K 31/7068 ^(2006.01) **A61K 33/243** ^(2019.01)
A61K 33/24 ^(2019.01) **A61P 35/00** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
A61K 31/506; A61K 31/337; A61K 31/475;
A61K 31/519; A61K 31/555; A61K 31/7048;
A61K 31/7068; A61K 33/24; A61K 33/243;
A61P 35/00 (Cont.)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: **12.02.2018 US 201862629166 P**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
19705720.1 / 3 752 153

(71) Applicant: **Astrazeneca AB**
151 85 Södertälje (SE)

(72) Inventor: **NASH, Anthony, Francis, Patrick**
Cambridge, SG8 6HB (GB)

(74) Representative: **AstraZeneca Intellectual Property**
Eastbrook House
Shaftesbury Road
Cambridge CB2 8BF (GB)

(54) **OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER**

(57) The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive

non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.

EP 4 431 154 A3

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/337, A61K 2300/00;

A61K 31/475, A61K 2300/00;

A61K 31/506, A61K 2300/00;

A61K 31/519, A61K 2300/00;

A61K 31/555, A61K 2300/00;

A61K 31/7048, A61K 2300/00;

A61K 31/7068, A61K 2300/00;

A61K 33/24, A61K 2300/00



EUROPEAN SEARCH REPORT

Application Number

EP 24 17 3629

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	SORIA JEAN-CHARLES ET AL: "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.", THE NEW ENGLAND JOURNAL OF MEDICINE 11 01 2018, vol. 378, no. 2, 11 January 2018 (2018-01-11), pages 113-125, XP002790155, ISSN: 1533-4406	1-14	INV. A61K31/506 A61K31/337 A61K31/475 A61K31/519 A61K31/555 A61K31/7048 A61K31/7068 A61K33/243 A61K33/24 A61P35/00
Y	* abstract * * page 114, right-hand column, paragraph first *	1-13	
X	GOSS GLENWOOD ET AL: "Osimertinib for pretreatedEGFRThr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 12, 14 October 2016 (2016-10-14), pages 1643-1652, XP029835817, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(16)30508-3	1-14	
Y	* abstract *	1-13	
X	MOK T S ET AL: "Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer", NEW ENGLAND JOURNAL OF MEDICINE, vol. 376, no. 7, 16 February 2017 (2017-02-16), pages 629-640, XP002790156,	1-14	
Y	* abstract * * page 630, paragraph "Trial Patients" *	1-13	
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
Munich		21 October 2024	Terenzi, Carla
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number

EP 24 17 3629

5

10

15

20

25

30

35

40

45

50

55

EPO FORM 1503 03.82 (P04C01)

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	YAGISHITA SHIGEHIO ET AL: "Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non-Small-Cell Lung Canc", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 91, no. 1, 13 October 2014 (2014-10-13), pages 140-148, XP029116218, ISSN: 0360-3016, DOI: 10.1016/J.IJROBP.2014.08.344 * abstract * * page 142, right-hand column, paragraph first * * page 142, right-hand column, line 38 - line 47 * * page 143, left-hand column, line 10 - right-hand column, line 1 * -----	1-13	
A	YOON STEPHANIE M ET AL: "Therapeutic management options for stage III non-small cell lung cancer.", WORLD JOURNAL OF CLINICAL ONCOLOGY 10 FEB 2017, vol. 8, no. 1, 10 February 2017 (2017-02-10), pages 1-20, XP002790157, ISSN: 2218-4333 * abstract * * page 5, right-hand column, line 55 - page 6, left-hand column, line 9 * * page 7, left-hand column, line 54 - line 57 * ----- -/-	1-14	TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 21 October 2024	Examiner Terenzi, Carla
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			



EUROPEAN SEARCH REPORT

Application Number

EP 24 17 3629

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X, P	SHUN L: "Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)", JOURNAL OF THORACIC ONCOLOGY - IASLC 19TH WORLD CONFERENCE ON LUNG CANCER 20181001 ELSEVIER INC. NLD, vol. 13, no. 10, Supplement, 1 October 2018 (2018-10-01), XP002790158, ISSN: 1556-0864 * page s497, paragraph P1.01-88 * -----	1-14	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 21 October 2024	Examiner Terenzi, Carla
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

1
EPO FORM 1503 03.82 (P04C01)